The quieter app may be the better care model

Not every successful digital-health product needs to be more elaborate than the last. The THRIVE trial studied an application for women taking adjuvant endocrine therapy after early breast cancer: an app alone, the app with tailored feedback, or enhanced usual care. The newly published economic analysis asks a practical question: if a modest digital intervention helps manage follow-up, do the benefits justify what patients and clinicians spend on it?

Of 304 randomized participants, 214 had complete economic data. Mean one-year societal costs were $11,596 in enhanced usual care, $6,682 with the app alone, and $11,408 with app-plus-feedback. Estimated quality-adjusted life-years were similar at roughly 0.78–0.79. But the app-only cost difference had a wide 95% confidence interval, approximately −$12,864 to +$3,036, so this is not a definitive cost-saving claim. Sensitivity modeling assigned the app-only strategy a 68%–78% probability of cost-effectiveness across stated thresholds.

The crucial context comes from the original randomized clinical-outcomes report: the intervention did not significantly improve endocrine-therapy adherence, even though some healthcare utilization measures moved. This economic analysis reuses that same trial population, so it must not be counted as independent clinical replication.